Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
企業コードPSTV
会社名Plus Therapeutics Inc
上場日Aug 09, 2000
最高経営責任者「CEO」Dr. Marc H. Hedrick, M.D.
従業員数21
証券種類Ordinary Share
決算期末Aug 09
本社所在地4200 Marathon Blvd.
都市AUSTIN
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号78756
電話番号17372557194
ウェブサイトhttp://www.plustherapeutics.com/
企業コードPSTV
上場日Aug 09, 2000
最高経営責任者「CEO」Dr. Marc H. Hedrick, M.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし